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Our objective was to determine the impact of telemedicine (TM) interventions on the management of type 1 diabetes (T1DM)
in youth. We performed a systematic review of randomized trials that evaluated TM interventions involving transmission of
blood glucose data followed by unsolicited scheduled clinician feedback. We found no apparent effect of the TM interventions
on hemoglobin A1c (HbA1c), severe hypoglycemia, or diabetic ketoacidosis. The limited data available on patient satisfaction,
quality of life, and cost also suggested no differences between groups. It is unlikely that TM interventions, as performed in the
assessed studies, had a substantial effect on glycemic control or acute complications. However, it remains possible that there are
other benefits of TM not adequately reported, that newer TM strategies may be more effective and that interventions may benefit
subgroups of youth, such as those with the poor glycemic control, adolescents, or those living in remote areas.
1. Introduction
Intensive glycemic control delays and prevents microvascular
and macrovascular complications of type 1 diabetes (T1DM)
[1, 2]. Despite advances in insulin preparations and delivery
mechanisms for insulin, glycemic control for many pediatric
patients with T1DM remains suboptimal. An international
study comparing glycemic control among pediatric diabetes
centres failed to show a correlation with insulin regimen,
suggesting that other factors, such as the organization of
delivery of care and the number of staff on the diabetes
team, may be critical to attaining optimal blood glucose
control [3].
The intensive treatment protocol used in the Diabetes
Control and Complications Trial (DCCT) included tele-
phone contacts to adjust insulin regimens daily for the
first week and then weekly thereafter. The intervention also
involved an intensive insulin regimen, increased frequency
of clinic visits, and intensive blood glucose monitoring
[4]. Although shown to be effective in improving glycemic
control, these intensive measures are not feasible to carry out
in routine practice.
Moreover, the particular challenges presented by youth
with T1DM necessitate innovative management strategies
[5]. One strategy for improving glycemic control is the
use of telemedicine (TM). We distinguish routine T1DM
management that may include solicited remote commu-
nication between patients and the diabetes team on an
as-needed basis from TM interventions as defined in
our study. We define TM to be the scheduled remote
transmission of blood glucose (BG) data by means such
as telephone, fax, mobile phone, or internet with unso-
licited clinician feedback. This definition of TM is con-
sistent with that used previously by authors of systematic
reviews on this topic in the adult population with T1DM
[6].
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The impact of these types of interventions on the
management of youth with T1DM is unknown. A previous
systematic review that included studies published up to July
2004 in adults and youth with all types of diabetes [7] and
another that included studies up to June 2003 in adults
and youth with T1DM [6] both report no effect of TM on
glycemic control. Since that time, new technologies such
as short message service (SMS) have become more widely
accessible to and utilized by youth.
Our objective is to assess the impact of TM interventions
on glycemic control in youth with T1DM. We report the
results of an updated systematic review that includes seven
new randomized trials, focuses only on the impact of TM
for T1DM in youth, and uses rigorous methodology. We also
identify a need to obtain additional data on potential benefits
of using telemedicine in clinical practice that extend beyond
its impact on glycemic control, including engaging and
empowering adolescents with novel technologies, improving
patient and family quality of life, and enhancing patient and
family education.
2. Methods
MEDLINE, EMBASE, CCTR, CINAHL (EBSCOHost), ISI
Web of Science, and clinicaltrials.gov were searched up to
December 21, 2009 without language restriction. Available
indexing terms and text words for T1DM, TM, or related
terms, and randomized controlled (RCT) or controlled
clinical trials (CCT) were used. The Telemedicine Infor-
mation Exchange (an international searchable database of
telemedicine citations), relevant conference abstracts from
2007-2008, and reference lists of included studies were also
searched.
Eligibility criteria for study inclusion were (1) youth less
than 19 years with T1DM; (2) TM interventions involving
scheduled routine transmission of blood glucose (BG) data
with unsolicited scheduled clinician feedback; (3) inclusion
of a control group that did not receive unsolicited feedback
about transmitted BG data; (4) RCT or CCT. Studies were
excluded if participants were pregnant or had non-T1DM.
Two reviewers independently assessed studies for eligibility
and validity and extracted data. Disagreements were resolved
through consultation with a third reviewer. Assessment of
study validity was done using the Cochrane Collaboration’s
tool for assessing risk of bias [8]. The Grades of Recommen-
dation, Assessment, Development, and Evaluation (GRADE)
system was used to assess the quality of the body of evidence.
The primary outcome assessed was HbA1c as a marker
of long-term complications of diabetes. Treatment effect was
expressed as a mean difference with 95% CI for continuous
outcomes and as an odds ratio (OR) with 95% CI for
dichotomous outcomes. Meta-analyses using a random-
effects model were performed using ReviewManager Version
5.0 software. We used the I2 statistic to determine the pro-
portion of variation in study estimates due to heterogeneity.
Publication bias was assessed using funnel plots.
We hypothesized, a priori, that the following fac-
tors may explain heterogeneity (variability in participants,
interventions, outcomes, study design, and risk of bias
among studies): (1) age, (2) baseline HbA1c, (3) frequency of
data transmission, and (4) timing of outcome measurement.
Insufficient data prohibited within-study comparisons to test
these hypotheses; however, between-study comparisons were
performed.
3. Results
Of 434 studies identified, 377 were excluded after review of
titles and abstracts because they were duplicates or involved
the wrong population, intervention, and/or study design; 57
studies were retrieved in full text. Ten studies, involving 609
youth, met eligibility criteria [9–18] (see Figure 1 for details
of the process of the selection of studies for inclusion and
Table 1 for study characteristics). Data from nine of the
ten studies were included in the meta-analysis. Data from
one study [13] was excluded because the primary outcome,
HbA1c, was reported as a modeled HbA1c effect and
therefore could not statistically be combined with outcomes
reported in the other studies. We report the results from this
study separately.
The shortest study lasted 3 months and the longest 12
months. Most studies were 6 months in duration. All studies
involved a minimum of every two-week frequency of data
transmission except one that had a school-based monthly
videoconference [13]. Clinic visits were held every three
months, except in one study [17] in which patients attended
clinic only every 6 months (Table 1). Most studies used
telephone, modem, or fax to transmit data. One [18] used
SMS, and one used videoconference [13]. Themean age of all
participants ranged from 10 to 17 years. Most studies limited
inclusion criteria to participants with suboptimal glycemic
control. The mean baseline HbA1c in the studies included in
the meta-analysis ranged from 8.2% to 10.2% (Table 2).
For all outcomes, the quality of the body of evidence
was downgraded because of elements of study design and
execution (Table 3) and because the GRADE system to assess
quality of evidence necessitates a downgrade for the use
of any indirect measure, such as HbA1c as a marker for
long-term complications [8]. The evidence regarding severe
hypoglycemia and DKA was also downgraded because rare
event rates and wide confidence intervals reflect uncertainty
about the estimate of effect. Therefore, for glycemic control,
severe hypoglycaemia, and DKA, the quality evidence is
graded as low (Table 4).
There was no statistically significant effect of TM on
HbA1c (mean difference −0.12, 95% CI, −0.35 to 0.11) with
no contribution of statistical heterogeneity to the variability
in effect estimate (I2 = 0%) (Figure 2(a)). Data from the
single study not included in the meta-analysis [13] showed
a significant difference in slope of the modelled HbA1c effect
between the TM and control groups during the first six
months of the intervention (P < .02), but none after the six
month point. The absolute decrease in the modelled HbA1c
in the TM group at six months was less than 0.5%.
Between-study comparisons based on age, baseline
HbA1c, frequency of data transmission, and timing of
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Table 1: Study characteristics of the 10 studies that met inclusion criteria.
Lead author, year (ref) Sample size
Frequency and mode of
data transmission and
feedback
Duration
(months)
Cointerventions
Frequency of
clinic visits
(months)
Study design
Cadario, 2007 [9] 28
2 weeks via modem,
clinician within 1 week
6 None 3 RCT
Chase, 2000 [10] 70
2 weeks via modem,
clinician by telephone
6 None
3 (TM group did
not attend at 3
months)
RCT
Gay, 2006 [11] 100
2 weeks, printout of
glucometer data faxed,
pediatric endocrinologist
advice by mail or phone
within 5 days
6 None 3 RCT
Howe, 2005 [12] 75
TM plus ED: weekly phone
calls for 3 months, then
bimonthly for 3 months
with diabetes nurse
educator
6 Education session 3 RCT, 3-arms
Izquierdo, 2009 [13] 41
Monthly videoconference
with immediate feedback
12 Education modules 3
RCT, ran-
domization
at the school
level
Lawson, 2005 [14] 46
Weekly telephone contact
with diabetes nurse
educator
6 None 3
RCT, single-
blinded,
parallel
design
Marrero, 1995 [15] 106
2 weeks, data management
system reviewed by
clinician, feedback
frequency determined by
algorithms
12 None 3
RCT,
repeated
measures
design
Nunn, 2006 [16] 123
Bimonthly phone calls with
nurse educator
5−8
Educational program
by phone using
written material and
illustrations
3 RCT
Panagiotopoulos, 2003
[17]
50
Phone contact with
educator 1-2 times weekly
6
Education provided
during calls and teen
issues addressed
6 RCT
Rami, 2006 [18] 36
Every BG checked or at
least daily via short
message service (SMS),
reviewed weekly by
diabetologist with SMS
feedback
3 None 3
Randomized
cross-over
trial
HbA1c measurement revealed no differences in pooled
estimates between subgroups. A post hoc between-study
comparison based on whether feedback was given in real-
time or if it was stored and forwarded also found no differ-
ence in HbA1c at the end of the intervention. The pooled
estimate for a between-study analysis comparing studies with
mean baseline HbA1c values <9.0% to those with ≥9.0%
trended toward favoring TM in the subgroup of studies
with baseline HbA1c ≥9% (Figure 3). Publication bias was
unlikely based on visual examination of the funnel plot.
Five studies reported frequency of severe hypoglycaemia
and DKA [9, 10, 13, 14, 18]. The pooled estimates revealed
no effect on severe hypoglycemia (OR 1.42, 95% CI, 0.22 to
9.32) or DKA (OR 1.02, 95% CI, 0.24 to 4.23) (Figures 2(b)
and 2(c)). A sensitivity analysis including data from the study
not included in the meta-analysis [13] did not significantly
change the pooled estimate for severe hypoglycemia or DKA.
However, the school-based study did find a decrease
in urgent visits to the school nurses for diabetes-related
problems and urgent calls to the diabetes center in the TM
group compared to control [13]. Of studies included in the
meta-analysis, patient satisfaction could be assessed in only
one study [10] and showed no significant difference between
groups. The school-based study [13] assessed patient satis-
faction in the intervention group only and found that 91% of
participants would use the telemedicine services again. Three
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Table 2: HbA1c at baseline and at end of intervention of the 9 studies included in the meta-analysis.
Study
HbA1c Inclusion
criteria
Mean (SD) HbA1c
baseline control (%)
Change in mean
HbA1c at followup
control (%)
Mean (SD) HbA1c
baseline TM (%)
Change in mean
HbA1c at followup
TM (%)
Cadario >7.0% ∗9.2 +0.2 ∗9.1 0
Chase 7.0%−13.0% 8.9 (1.1) −0.3 9.0 (1.2) −0.4
Gay ≥8.0% 9.2 (0.9) +0.1 9.3 (1.3) −0.2
Howe >8.5%
10.2 (1.4), ED 10.1
(1.2)
−0.5 10.0 (1.4) −0.5
Lawson >8.5% 9.7 (0.6) −0.1 10.0 (1.3) −0.6
Marrero None defined 9.9 (1.6) +0.4 9.4 (1.9) +0.6
Nunn >8.0% 8.3 (1.0) +0.5 8.2 (1.1) +0.7
Panagiotopoulos ≥8.0% but <14.0% 9.6 (1.3) −0.5 9.7 (1.2) −0.9
Rami ≥8.0% †9.3 (8.3−11.6) +0.4 †9.1 (8.0−11.3) −0.1
ED: education.
∗No measure of variance reported.
†Median (range).
Table 3: Risk of Assessment of Bias of the 10 studies that met inclusion criteria.
Study
Sequence
generation
Allocation
concealment
Blinding of
healthcare
providers
Blinding of data
collectors
Blinding of data
analyzers
Incomplete
outcome data
Selective
outcome
reporting
Cadario 2007 Unsure Unsure Unsure Unsure Unsure Inadequate Adequate
Chase 2003 Unsure Unsure Adequate Unsure Unsure Inadequate Adequate
Gay 2006 Adequate Unsure Unsure Unsure Unsure Inadequate Inadequate
Howe 2005 Adequate Unsure Unsure Unsure Unsure Inadequate Adequate
Izquierdo 2009 Unsure Unsure Unsure Unsure Unsure Inadequate Adequate
Lawson 2005 Adequate Adequate Adequate Adequate Adequate Adequate Adequate
Marrero 1995 Unsure Unsure Unsure Unsure Unsure Unsure Adequate
Nunn 2006 Adequate Unsure Inadequate Unsure Unsure Adequate Adequate
Panagiotopoulos
2003
Adequate Unsure Unsure Unsure Unsure Adequate Inadequate
Rami 2006 Unsure Unsure Unsure Unsure Unsure Adequate Adequate
Refer to the Cochrane Collaboration’s tool for assessing risk of bias [8] for the methods used to assess the risk of bias in studies.
studies reported diabetes-related quality of life (QoL) [13–
15], and none found significant differences between groups.
Only two studies [9, 10] reported the cost of a clinic visit;
in one of these [10], the TM group did not attend the three-
month visit with a cost savings of $USD 142.00. Indirect costs
such as missed work and school were considered [10] but not
converted into dollar value nor incorporated in the overall
cost calculation.
4. Discussion
Our results indicate that, despite a significant increase in new
studies, no robust effect of TM on HbA1c was observed at
the end of the intervention. It remains possible that TM has
a small effect on HbA1c, but our data argue against a large
effect. Our pooled analysis includes more than 100 subjects
per group giving us enough power to detect a difference
in HbA1c of 0.5%. Therefore, if there is an effect of the
intervention on HbA1c, it is likely less than 0.5%. Our results
are consistent with a recent randomized control trial examin-
ing the effect of telemedicine case management for diabetes
in an older population. This study involving 1,665 subjects
found an estimated 0.29% difference in HbA1c favoring
telemedicine at the end of 5 years between groups [20].
We do not believe that lack of effect stems from selection
bias among included studies. We did not expand our defini-
tion to include all uses of telemedicine, including web-based
education modules and teleconferences to conduct remote
clinic visits that did not necessarily include routine transmis-
sion of and feedback on blood glucose results, because that
would have resulted in a collection of heterogeneous inter-
ventions among which a combination and comparison of
outcomes would have been inappropriate in a meta-analysis.
Moreover, upon reviewing studies that were excluded by our
methods, we found that the results of those studies excluded
were similar to those that were included. Three randomized
controlled trials that were excluded from our review, because
they did not involve transmission of blood glucose data, also
found no effect on glycemic control [21–23].
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Titles and abstracts screened (246)
Duplicates (188)
Excluded (189)
Studies selected for inclusion (10)
Excluded (47)
Wrong population, intervention, or study design (45)
Citations identified by electronic
database search (434)
Wrong population (39), intervention (61), study
design (7), or more than one exclusion (82)
Potentially relevant studies retrieved in full
text (57)
Satisfied eligibility criteria but no transmission
of data (2)
Either reviewer rated “include” or “unsure”
Figure 1: Process of selection of studies for inclusion.
Episodes of severe hypoglycemia and DKA were rare
and did not differ between groups. Although data were
limited, there were no apparent differences in QoL or
patient satisfaction between groups. One study that used
TM to replace a clinic visit suggests a reduction in cost
with no increase in adverse effects. Although we might have
expected adolescents to be more engaged in a telemedicine
intervention compared to younger children, a between-study
comparison found no differences in pooled estimates of
HbA1c at the end of the intervention between subgroups
based on age. However, it is possible that future, more
technology-based interventions may fare better.
We used the GRADE system because it provides explicit
and comprehensive criteria for assessing the quality of a body
of evidence. We recognize that based on this system, the
evidence in our study was determined to be low. This was,
in part, due to a necessary downgrade for the use of HbA1c
as an indirect measure. However, based on the results of
the DCCT [1, 2], HbA1c is regarded as a reliable surrogate
marker for long-term complications in T1DM. Therefore,
the quality of evidence is likely better than is reflected by the
GRADE system.
Despite disappointing initial results, many aspects of TM
interventions warrant further study. For example, between-
study subgroup analyses suggest a trend toward a greater
effect of TM on HbA1c among participants with the highest
baseline HbA1c. Thus, determining whether TM could be
an important adjunct for patients with the poorest glycemic
control is worth further investigation in well designed,
adequately powered, long-term studies.
Although our study found no overall effect on glycemic
control, it did not identify any detrimental effects. Thus,
other factors to consider include whether TM may be
more effective in subgroups of youth such as those living
remotely from the centres where care is provided. Reducing
the number of clinic visits, while maintaining glycemic
control, would be clinically desirable and potentially cost-
effective. Thus, more studies are also needed to examine
the cost-utility of TM and to determine the effects of TM
interventions that replace aspects of diabetes care. Such
studies should consider if TM would result in missed
opportunities for screening for complications and/or educa-
tion.
Finally, it will also be important to determine whether
the effect of TM differs depending on the expertise of the
individuals administering the TM, the frequency, and mode
of data transmission (SMS, email, mobile phone, smart
phone, personal digital assistant (PDA)) and whether the
intervention involves the youth and/or their caregivers, or the
setting. One study that examined TM in the school setting
found that there was a decrease in the number of urgent visits
to school nurses and calls to the diabetes centers. Successful
implementation of a school-based TM intervention depends
on the particular structure of the school system and may not
be feasible where there are no school nurses.
It was surprising that more of the recent studies did
not use more novel modes of data transmission such as
SMS or other telephone-based strategies. It is possible that
future studies examining the effects of newer technologies
may show different results compared to the studies currently
available for review. In addition to glycemic control and
complications, such studies should measure other patient-
important outcomes such as QoL, diabetes knowledge, and
patient satisfaction.
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Study 
Rami 
Cadario 
Howe 
Panagiotopoulos 
Chase 
Marrero 
Gay
Lawson 
Nunn 
Total (95% CI)
Mean
9
9.1
9.5
8.8
8.6
10
9.1
9.4
8.9
SD
3.4
1.6
1.7
1.3
1.2
1.6
1.5
1.4
1.3
Total
18
14
26
25
30
52
36
23
63
287
Mean
9.7
9.4
9.7
9.1
8.6
10.3
9.3
9.6
8.8
SD
3.3
1.5
1.9
1.4
1.7
1.8
1.2
0.3
1.1
Total
18
12
21
25
33
54
35
23
60
281
3.7%
Weight
1.1%
4.9%
9.4%
10.2%
12.6%
13.3%
15.5%
29.3%
100%
Random, 95% CI
Control Mean difference Mean difference
IV, random, 95% CI
0 1 2
Favours TM Favours control
TM
Heterogeneity: Tau2 = 0; Chi2 = 2.17, df = 8 (P = .98); I2 = 0%
−0.7 [−2.89, 1.49]
−0.3 [−1.49, 0.89]
−0.2 [−1.24, 0.84]
−0.3 [−1.05, 0.45]
0 [−0.72, 0.72]
−0.3 [−0.95, 0.35]
−0.2 [−0.83, 0.43]
−0.2 [−0.79, 0.39]
0.1 [−0.32, 0.52]
−0.12 [−0.35, 0.11]
Test for overall effect: Z = 1.05 (P =.29) −2 −1
(a) HbA1c at the end of the intervention
Study 
Cadario 
Chase 
Lawson 
Rami 
Total (95% CI)
log[odds ratio]
1.02
0.09
0
0
SE
1.68
2.02
2.02
2.03
Weight
32.6%
22.5%
22.5%
22.3%
100%
Random, 95% CI
2.77 [0.1, 74.64]
1.09 [0.02, 57.35]
1.42 [0.22, 9.32]
Odds ratio Odds ratio
IV, Random, 95% CI
0.001 0.1 1 10 1000
Favours TM Favours control
Heterogeneity: Tau2 = 0; Chi2 = 0.24, df = 3 (P = .97); I2 = 0%
1 [0.02, 52.41]
1 [0.02, 53.45]
Test for overall effect: Z =0.37 (P =.71)
(b) Frequency of severe hypoglycemia
Study or subgroup
Cadario 2007
Chase 2003
Lawson 2005
Rami 2006
Total (95% CI)
log[odds ratio]
0.097
0
0
SE
2.037
1.182
2.021
1.203
Weight
12.7%
37.8%
12.9%
36.5%
100.0%
Random, 95% CI
0.86 [0.02, 46.73]
1.02 [0.24, 4.23]
Odds ratio Odds ratio
IV, Random, 95% CI
0.001 0.1 1 10 1000
Favours experimental Favours control
Heterogeneity: Tau2 = 0; Chi2 = 0.01, df = 3 (P = 1); I2 = 0%
1.1 [0.11, 11.17]
1 [0.02, 52.51]
1 [0.09, 10.57]
Test for overall effect: Z = 0.02 (P =.98)
−0.148
(c) Frequency of DKA
Figure 2: Meta-analysis of the effect of TM. Weight assigned to each study was determined using the inverse variance (IV) method which
assigns weight based on the inverse of the variance of the effect estimate (one over the square of the standard error). Studies with smaller
standard errors are given more weight than those with larger standard errors [19]. The size of the square representing the measure of effect
is proportional to the percent weight assigned to each study on the forest plot.
5. Conclusions
In its recommendations about the structure of pediatric
diabetes care the International Society for Pediatric and
Adolescent Diabetes (ISPAD) recommends the use of TM
for patients living remotely from diabetes centres and
acknowledges that TM may result in improved diabetes
management in all areas [5]. Our paper will likely not change
current practice as diabetes care clinics will have to embrace
these novel forms of communication to mirror what patients
are using. Because of the small number and variable nature
of the available studies, we have tried to be careful not
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Study or Subgroup
Baseline HbA1c 9% or greater
Cadario 
Gay 
Howe 
Lawson 
Marrero 
Panagiotopoulos 
Rami 
Chase 
Nunn 
Mean
9.1
9.1
9.5
9.4
10
8.8
9
8.6
8.9
SD
1.6
1.5
1.7
1.4
1.6
1.3
3.4
1.2
1.3
Total
14
36
26
23
52
25
18
30
63
Telemedicine
8.6
8.8
1.7
1.1
33
60
25.7%
74.3%
Mean
9.4
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Figure 3: Meta-analysis of HbA1c at the end of the intervention with between-study comparison based on baseline HbA1c values. Weight
assigned to each study was determined using the inverse variance (IV) method which assigns weight based on the inverse of the variance of
the effect estimate (one over the square of the standard error). Studies with smaller standard errors are given more weight than those with
larger standard errors [19]. The size of the square representing the measure of effect is proportional to the percent weight assigned to each
study on the forest plot.
to overinterpret our results. However, given the potential
monetary and personnel costs involved in implementing TM
strategies, our paper does emphasize that TM should be well
studied before it is embraced and that care must be taken
to identify which subgroups of patients would maximally
benefit and how we should deliver TM in the most time and
resource efficient manner.
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